Clinical trials: HFpEF - Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction, Functional Mitral Regurgitation
Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation
The main objective of this study is to assess the hemodynamic effects of sacubitril-valsartan in patients with heart failure with preserved ejection fraction and at least moderate atrial functional mitral regurgitation (AFMR)…
- Trial name
- PRAISE-MR (NCT05991284)
- Testing
- Sacubitril-valsartan, Standard of care
- Where
- Belgium
- Volunteers
- 84 people
- Sponsor
- Ziekenhuis Oost-Limburg
Atrial Fibrillation (Paroxysmal), Hypertension
Renal Denervation in Patients With Atrial Fibrillation and Hypertension
High blood pressure is a major risk factor for atrial fibrillation (AF), an irregular heart rhythm, and heart failure with preserved ejection fraction (HFpEF), a condition in which the heart becomes stiff and cannot relax…
- Conditions
- Atrial Fibrillation (Paroxysmal), Hypertension, Heart Failure With Preserved Ejection Fraction (HFPEF)
- Trial name
- NCT07893821
- Testing
- Catheter-based renal artery electrical stimulation (as a feasibility assessment for renal denervation)
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Pavel Antiperovitch
Pulmonary Hypertension
A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041)
Researchers are looking for other ways to treat people with combined postcapillary and precapillary pulmonary hypertension (CpcPH).
- Trial name
- CHORUS (NCT07839585)
- Testing
- Sotatercept
- Volunteers
- 352 people
- Sponsor
- Merck Sharp & Dohme LLC
Atrial Fibrillation (AF)
Electroporation Treatment for Early AF Management in Heart Failure With Preserved Ejection Fraction (HFpEF) Pilot Study
The proposed pilot study is a prospective, randomized, single-center feasibility study, enrolling 200 patients with symptomatic paroxysmal AF.
- Trial name
- E-TEAM (NCT07385417)
- Testing
- AF Ablation
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Cardioangiologisches Centrum Bethanien
Acute Heart Failure
Acute Heart Failure With Preserved Ejection Fraction - COngestion Discharge Evaluation
The AHF-CODE preserved study is a prospective, non-randomized, monocenter study performed in patients with heart failure with preserved ejection fraction admitted for worsening heart failure.
- Trial name
- AHF-CODE-P (NCT04343430)
- Testing
- Clinical examination centered on congestion, Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography, Biological: Blood sample retrieved for biological assessment and biobanking
- Where
- France
- Volunteers
- 170 people
- Sponsor
- Central Hospital, Nancy, France
Heart Failure, Heart Failure With Reduced Ejection Fraction
Consistently Assess Signs and Symptom of Heart Failure
Heart failure (HF) is a major public health problem. The New York Heart Association (NYHA) Functional Classification by a HF provider helps to guide their decisions in patient treatment.
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
- Trial name
- CLASS-HF (NCT05833581)
- Testing
- New York Heart Association Classification Guide
- Where
- 3 sites in United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Board of Trustees of Illinois State University
Heart Failure, Diastolic
CCM in Heart Failure With Preserved Ejection Fraction
This pilot study will evaluate the efficacy and safety of CCM therapy in heart failure patients with baseline EF≥50% (HFpEF) who have New York Heart Association (NYHA) Class II or III symptoms despite appropriate medication.
- Trial name
- CCM-HFpEF (NCT03240237)
- Testing
- Optimizer SMART
- Where
- 17 sites in Australia, Czechia and 6 more
- Volunteers
- 47 people
- Sponsor
- Impulse Dynamics
Heart Failure With Preserved Ejection Fraction
Beta-blocker Discontinuation in Heart Failure With Preserved Ejection Fraction
This is a prospective pilot study to evaluate changes before and 4 weeks after beta-blocker withdrawal in 30 HFpEF patients.
- Trial name
- HFpEF-BB (NCT05174351)
- Testing
- beta blocker discontinuation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- UConn Health
Pulmonary Hypertension Associated With HFpEF
Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF
This was an open-label study to evaluate the safety of continued therapy with oral treprostinil in subjects who completed Study TDE-HF-301.
- Trial name
- NCT03043651
- Testing
- Oral treprostinil
- Where
- 82 sites in United States
- Volunteers
- 48 people
- Sponsor
- United Therapeutics
Heart Failure Preserved Ejection Fraction, Pregnancy Complications
Middle-aged Women With Adverse Pregnancy Outcomes and Heart Failure With Preserved Ejection Fraction
Due to the steady increase in the burden of HFpEF, especially in women, it is an important task to search for new markers and early predictors associated with the development of this disease.
- Trial name
- MAPO-HF (NCT06338943)
- Testing
- Echocardiography, Questionnaire
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Central Sleep Apnea, Heart Failure With Preserved Ejection Fraction
Quality of Sleep of Patients With Predominant Central Sleep Apnea Syndrome(SAS) Whose EF > 45% Treated by ASV
The main goal of this French multicenter observational cohort study is to prospectively collect data assessing the impact of the Adaptative Servo-Ventilation treatment on the quality of sleep of patients with central or combined…
- Trial name
- FACIL-VAA (NCT02835638)
- Testing
- Adaptative Servo Ventilation
- Where
- 28 sites in France
- Volunteers
- 520 people
- Sponsor
- Société Française de Recherche et de Médecine du Sommeil
Heart Failure With Preserved Ejection Fraction, Heart Diseases
Heart Failure With Preserved Ejection Fraction: Evaluation and Recognition by CMR
Heart failure with preserved ejection fraction (HFpEF) is a common and growing condition with a poor prognosis but the pathophysiology and management are still being investigated.
- Trial name
- PREFER-CMR (NCT05114785)
- Testing
- Multi Parametric Cardiac Magnetic Resonance
- Volunteers
- 100 people
- Sponsor
- University of East Anglia
Heart Failure with Preserved Ejection Fraction
Study on Heart Failure with Preserved Ejection Fraction with Qishen Granules
With the cardiopulmonary exercise testing as the primary outcome, the study aims to evaluate the efficacy of Qishen Granules on cardiac function, quality of life and biomarker level of patients with heart failure with preserved…
- Trial name
- NCT06377761
- Testing
- Qishen Granules
- Where
- 2 sites in China
- Volunteers
- 80 people
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
Heart Failure With Preserved Ejection Fraction
Association Between Coronary and Peripheral Vascular Injury in Heart Failure Patients With Preserved Ejection Fraction.
Heart failure with preserved ejection fraction (HPEF, defined as LVEF ≥50%) represents 50% of hospital admissions for heart failure.
- Trial name
- COROVASC (NCT05884346)
- Testing
- Ultrahigh-frequency ultrasound
- Where
- France
- Volunteers
- 84 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Heart Failure
Efficacy and Safety of Xinyue Capsule in the Treatment of Heart Failure With Preserved Ejection Fraction
The purpose of this study is to evaluate the effect of Xinyue Capsule in the improvement cardiac function and reduction the level of heart failure biomarker NT-proBNP in patients suffering from HF with an ejection fraction…
- Trial name
- NCT06946095
- Testing
- Chinese patent medicine
- Volunteers
- 246 people
- Sponsor
- Beijing Anzhen Hospital
Heart Failure With Preserved Ejection Fraction (HFpEF)
UK Heart Failure With Preserved Ejection Fraction
Heart failure occurs when the heart is no longer able to pump blood around the body properly. It can cause breathlessness, swollen feet and ankles, and tiredness.
- Trial name
- UK HFpEF (NCT05441839)
- Where
- 26 sites in United Kingdom
- Volunteers
- 10,000 people
- Sponsor
- Manchester University NHS Foundation Trust
Heart Failure With Preserved Ejection Fraction (HFPEF)
The Role of Epicardial Adiposity in Heart Failure With Preserved Ejection Fraction
In this study the investigators are aiming to recruit 130 patients with heart failure with preserved ejection fraction who are obese and non-obese to undergo CT and MRI scans, as well as some other investigations including blood…
- Trial name
- EAT HFpEF (NCT06768437)
- Where
- United Kingdom
- Volunteers
- 130 people
- Sponsor
- University of Leicester
Microvascular Coronary Artery Disease, Heart Failure With Reduced Ejection Fraction
CMR Assessment of Cardiac Microvascular Dysfunction in Patients With HFpEF
Heart failure with preserved ejection fraction (HFpEF) causes hospitalizations, premature mortality and high health care costs. This is also due to poor understanding of HFpEF pathogenesis and, thus, lack of specific therapies.
- Trial name
- MAPPED (NCT06316661)
- Testing
- stress perfusion cardiac magnetic resonance, cardiopulmonary exercise test
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Istituto Auxologico Italiano
Heart Failure, Diastolic
Physiologic Accelerated Pacing as a Treatment in Patients With Heart Failure With Preserved Ejection Fraction
Part I: Week 0-12: Quantify the effects of lower heart rate (HR) elevation on symptoms and function in patients with heart failure with preserved ejection fraction (HFpEF).
- Trial name
- PACE HFpEF (NCT04546555)
- Testing
- Dual chamber pacemaker, Accelerated Physiologic Pacing, Nocturnal Pacing
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Daniel L Lustgarten
Heart Failure with Preserved Ejection Fraction
Dapagliflozin in Reducing Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is becoming the most common cause of heart failure worldwide, in part, driven by a rising prevalence of obesity.
- Trial name
- NCT06510270
- Testing
- Dapagliflozin 10 mg once daily, Loop diuretics, Treatments of associated co-morbidities (e.g Anti-hypertensive, oral hypoglycemic)
- Volunteers
- 70 people
- Sponsor
- Aswan University